查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018768

T 細胞療法市場：2026-2032 年全球市場預測，按適應症、治療方法、生產模式、細胞來源和最終用戶分類。

T-Cell Therapy Market by Indication, Therapy Type, Manufacturing Model, Cell Source, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，T 細胞療法市值將達到 120.3 億美元，到 2026 年將成長至 146.9 億美元，到 2032 年將達到 478.2 億美元，複合年成長率為 21.79%。

主要市場統計數據
基準年 2025 120.3億美元
預計年份：2026年 146.9億美元
預測年份 2032 478.2億美元
複合年成長率 (%) 21.79%

臨床檢驗、製造技術成熟以及與醫療保健系統的整合如何影響現代 T 細胞療法在短期策略制定中的前景？

T細胞療法已從實驗科學發展成為先進免疫療法的關鍵支柱，重塑了臨床醫生和研發人員治療腫瘤、感染疾病和自體免疫疾病的方式。過去十年間，迭代式臨床驗證，以及細胞工程、載體設計和生產流程的進步，推動細胞產品從小眾臨床實驗藥物發展成為擁有明確監管路徑和商業化策略的治療方法。

基因工程、自動化製造和適應性監管合作的融合正在加速向平台主導的T 細胞療法生態系統的轉型。

在科學突破和商業擴張的共同推動下，T細胞療法領域正經歷一場變革。基因編輯工具和新一代受體工程技術正在拓展可安全靶向的抗原範圍，為過去難以治療的疾病提供以患者為中心的治療方案。同時，異體移植策略和現成製劑的成熟正在改變人們對治療啟動時間和庫存管理的預期，進而改變研發者、契約製造和臨床試驗中心之間的關係。

到 2025 年，貿易政策的累積影響加劇了供應鏈的脆弱性，並促使製造模式和臨床實驗供應計畫發生策略性轉變。

美國2025年實施的關稅和貿易政策調整產生了累積效應，波及整個T細胞療法價值鏈，影響投入、生產決策和國際合作。病毒載體、一次性耗材和特殊試劑等關鍵原料的採購通常涉及跨境供應商。關稅增加了接收成本，迫使各機構重新評估供應商選擇、庫存策略和短期資金配置。

透過對臨床環境、細胞來源、適應症、治療方法和生產方法進行詳細的細分分析，可以製定差異化的開發和商業策略。

細分市場分析揭示了不同臨床環境、生物製藥採購、治療重點、治療方式和營運模式所面臨的差異化策略挑戰。從終端使用者觀點來看，醫院仍然是實施複雜自體細胞治療方案的核心，這些方案需要受控的住院環境和多學科支援。同時，研究機構繼續推動早期創新和轉化科學的發展，而隨著治療流程和支持性護理的標準化，專科診所也擴大實施門診治療方案。

全球不同的監管環境、支付方環境和生產能力如何驅動差異化的市場進入和供應鏈策略。

區域趨勢影響從臨床開發到商業化和供應鏈調整的策略重點。在美洲，完善的臨床試驗基礎設施、密集的醫保報銷談判以及充足的生產能力，為臨床成果的快速實用化和早期商業化提供了支持。然而，控制成本的壓力以及區域健保報銷方案的差異，要求企業提出清晰的價值主張和創新的定價策略。

企業層面的競爭優勢越來越來自涵蓋平台科學、可擴展製造以及與支付方和監管機構積極互動等方面的綜合能力。

企業層面的關鍵洞察聚焦於能力整合、夥伴關係策略和垂直整合決策，這些因素決定了企業的競爭地位。主要企業正透過將受體工程專業知識與轉化管線結合來拓展其適應症範圍，而其他公司則專注於提升其平台的穩健性，以支援多個候選產品。合約開發和生產組織（CDMO）的角色正在從單純的生產環節轉變為策略合作夥伴，提供製程開發、分析服務和品質源自設計（QbD）能力，從而加快申辦方進入臨床試驗的時間。

透過整合製造自動化、供應鏈多元化、證據產生和相關人員合作，加速轉化研究和實用化的實用領導指南。

產業領導者應採取多管齊下的方法，將科學目標與實際操作結合。首先，應優先投資於製造自動化和封閉式系統製程開發，以降低變異性、減少對人工的依賴並縮短前置作業時間。這項營運基礎將有助於提高產品品質的穩定性，並靈活應對需求波動。

我們高度透明、經過三角檢驗的調查方法，結合了專家訪談、臨床和監管文件以及生產過程分析，確保了可靠且可操作的見解。

本執行摘要的研究採用三角驗證法，整合了一級資訊來源和二級資訊來源，以確保分析的嚴謹性和有效性。一級資訊來源包括對臨床研究人員、生產企業高管和監管顧問的結構化訪談，以及透過與支付方和醫院管理人員的諮詢會議收集的營運和報銷方面的觀點。這些定性資訊與公開的監管文件、同行評審文獻和行業資訊披露進行了系統性的交叉核對，以檢驗趨勢並識別宣稱的能力與實際營運績效之間的差異。

整合科學預期和營運挑戰：T 細胞療法的永續商業化需要一種涵蓋技術、監管和商業方面的綜合方法。

T細胞療法在現代醫學中佔據著變革性的地位，為腫瘤、感染疾病和自體免疫疾病提供了潛在的永續解決方案。在推動臨床突破的同時，該領域也面臨供應鏈、生產和醫保報銷等方面的現實挑戰，這些挑戰決定著患者獲得治療的速度。對於致力於將科學預期轉化為持久臨床和商業性影響的機構而言，在細胞來源、治療方法、生產模式和區域部署等方面做出策略決策至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：T細胞療法市場：依適應症分類

  • 自體免疫疾病
    • 多發性硬化症
    • 銀屑病
    • 類風濕性關節炎
  • 感染疾病
    • B型肝炎
    • C型肝炎
    • HIV
  • 腫瘤學
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
    • 固體癌
      • 乳癌
      • 肺癌
      • 惡性黑色素瘤

第9章 T細胞療法市場依治療方法分類

  • CAR-T細胞療法
  • TCR T細胞療法
  • TIL療法

第10章：以生產模式分類的T細胞療法市場

  • 契約製造
  • 內部生產

第11章 T細胞療法市場（按細胞來源分類）

  • 同種
  • 自有住房

第12章 T細胞療法市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第13章：T細胞療法市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 T細胞療法市集：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：T細胞療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 美國T細胞療法市場

第17章 中國T細胞治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adaptimmune Therapeutics PLC
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics PLC
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • Caribou Biosciences, Inc.
  • Cartesian Therapeutics, Inc.
  • Cellectis SA
  • CRISPR Therapeutics AG
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Gracell Biotechnologies Inc.
  • Immatics Biotechnologies GmbH
  • Immunocore Ltd.
  • IN8Bio, Inc.
  • Johnson & Johnson Services, Inc.
  • Mustang Bio, Inc.
  • Novartis AG
  • Poseida Therapeutics, Inc.
  • Precision BioSciences, Inc.
  • Tmunity Therapeutics, Inc.
  • Vor Biopharma, Inc.
Product Code: MRR-A26E0E5744D4

The T-Cell Therapy Market was valued at USD 12.03 billion in 2025 and is projected to grow to USD 14.69 billion in 2026, with a CAGR of 21.79%, reaching USD 47.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.03 billion
Estimated Year [2026] USD 14.69 billion
Forecast Year [2032] USD 47.82 billion
CAGR (%) 21.79%

How clinical validation, manufacturing maturation, and health system adoption are collectively shaping the modern T-cell therapy landscape for near-term strategic planning

T-cell therapies have moved from experimental science to a critical pillar of advanced immunotherapy, reshaping how clinicians and developers approach treatment of oncology, infectious, and autoimmune conditions. Over the past decade, iterative clinical proof points combined with advances in cell engineering, vector design, and manufacturing processes have transitioned cellular products from niche investigational agents to therapies with defined regulatory pathways and commercialization strategies.

The industry now confronts a dual imperative: to sustain scientific momentum while solving practical constraints associated with scalability, cost management, and global supply chain resiliency. As developers refine antigen targeting and persistence profiles, healthcare systems and payers must evolve assessment frameworks for clinical value and long-term safety. Meanwhile, manufacturing innovations and strategic partnerships are becoming as decisive as clinical differentiation in determining a therapy's commercial fate.

Consequently, stakeholders must balance near-term operational decisions with longer-term investments in platform technologies, workforce capabilities, and regulatory engagement. The remainder of this executive summary synthesizes the transformative shifts, segmentation intelligence, regional dynamics, and pragmatic recommendations that leaders can leverage to accelerate clinical translation and sustainable commercialization.

Convergence of gene engineering, automated manufacturing, and adaptive regulatory engagement is accelerating the transition to platform-driven T-cell therapy ecosystems

The T-cell therapy landscape is undergoing transformative shifts driven by convergence of scientific breakthroughs and operational scaling. Gene editing tools and next-generation receptor engineering have expanded the kinds of antigens that can be safely targeted, enabling tailored approaches for previously intractable indications. Concurrently, the maturation of allogeneic strategies and off-the-shelf constructs is changing expectations around time-to-treatment and inventory management, which in turn alters the relationships between developers, contract manufacturers, and clinical sites.

Manufacturing has evolved from artisanal, patient-specific workflows to hybridized models that incorporate automation, closed systems, and modular production lines. This operational evolution reduces manual variability, compresses batch turnaround times, and enables capacity to support broader clinical programs. Furthermore, digitalization of production data and quality systems has improved traceability and regulatory readiness, while also creating opportunities to apply predictive analytics for yield optimization.

Regulatory engagement and payer interactions represent another axis of change. Authorities are increasingly receptive to adaptive trial designs and real-world evidence as complementary sources of safety and effectiveness data. At the same time, payers demand evidence that aligns clinical benefit with durable outcomes and economic value. These pressures are prompting developers to design evidence-generation strategies that blend randomized data with registries and health-economic modeling. In combination, these scientific, operational, and commercial shifts are accelerating a transition from single-product innovation to platform-driven, sustainable therapeutic ecosystems.

Cumulative trade policy effects in 2025 amplified supply chain sensitivities and prompted strategic shifts in manufacturing models and trial supply planning

The introduction of tariffs and trade policy adjustments in the United States during 2025 created a cumulative set of impacts that ripple through the T-cell therapy value chain, affecting inputs, manufacturing decisions, and international collaborations. Sourcing of critical raw materials such as viral vectors, single-use consumables, and specialized reagents often involves cross-border suppliers; tariffs increase landed costs and force organizations to reassess supplier selection, inventory strategies, and near-term capital allocation.

In response, many developers and contract manufacturers reevaluated their manufacturing models, weighing the benefits of contract manufacturing partnerships against the strategic control afforded by in-house production. Organizations operating global supply networks increased buffer inventories and diversified supplier bases to mitigate tariff-driven price volatility. At the same time, some companies accelerated localization of key production steps to jurisdictions with more stable trade arrangements, which created logistical and regulatory complexities but reduced exposure to import duties.

Clinically, tariff-driven cost pressures affected trial supply planning and timelines, particularly for multi-regional studies reliant on centralized manufacturing. Sponsors adjusted enrollment pacing or adopted decentralized manufacturing strategies to preserve trial continuity. Commercially, higher input costs intensified discussions with payers around innovative contracting and risk-sharing mechanisms that account for manufacturing cost inflation. Overall, the cumulative impact of tariffs in 2025 emphasized the need for supply chain hedging, flexible manufacturing footprints, and proactive stakeholder alignment to preserve both clinical momentum and commercial viability.

Deep segmentation intelligence across clinical settings, cell origins, indications, modalities, and manufacturing choices that informs differentiated development and commercial strategies

Segmentation analysis reveals differentiated strategic imperatives across clinical settings, biologic sourcing, therapeutic focus, modality, and operational delivery models. When viewing the market through the lens of end-user environments, hospitals remain central for delivering complex autologous protocols that require controlled inpatient settings and multidisciplinary support, whereas research institutes continue to drive early-phase innovation and translational science, and specialty clinics increasingly host outpatient-capable protocols as procedures and supportive care become more standardized.

Examining cell source segmentation underscores fundamental trade-offs between allogeneic and autologous approaches. Autologous constructs historically offered personalized antigen recognition with established regulatory precedents but required patient-specific manufacturing logistics. Conversely, allogeneic constructs promise scale and reduced time-to-treatment but introduce immunogenicity and engraftment considerations that necessitate distinct clinical strategies and manufacturing controls.

Indication segmentation highlights how therapeutic priorities and evidence requirements vary by disease area. Oncology programs demand durable remissions and careful management of acute toxicities, while infectious disease and autoimmune indications require different efficacy endpoints and safety tolerances. Within autoimmune diseases, conditions such as multiple sclerosis, psoriasis, and rheumatoid arthritis present distinct pathophysiologic targets and patient populations that influence trial design. For infectious diseases, hepatitis B, hepatitis C, and HIV each require tailored virologic and immunologic endpoints. Oncology indications span hematologic malignancies like leukemia, lymphoma, and multiple myeloma to solid tumors, where breast cancer, lung cancer, and melanoma each impose unique tumor microenvironmental constraints that affect cell trafficking and persistence.

Therapy type segmentation elucidates differences among CAR T cell therapy, TCR T cell therapy, and TIL therapy in terms of antigen recognition, manufacturing complexity, and clinical deployment. CAR T modalities offer robust responses in hematologic malignancies and rely on engineered receptor constructs, whereas TCR therapies expand the antigen repertoire including intracellular targets, and TIL therapies leverage tumor-resident lymphocytes for solid tumor immunogenicity. Finally, manufacturing model segmentation-positioning organizations between contract manufacturing and in-house production-frames strategic choices about capital investment, control over quality systems, and the ability to scale rapidly in response to clinical or commercial demand. Each segmentation axis therefore informs prioritization of R&D investments, operational design, and market engagement strategies.

How distinct regulatory environments, payer landscapes, and manufacturing capacities across global regions drive differentiated go-to-market and supply chain strategies

Regional dynamics shape strategic priorities from clinical development through commercialization and supply chain orchestration. In the Americas, robust clinical trial infrastructure, concentrated reimbursement dialogues, and substantial manufacturing capacity favor accelerated clinical translation and early commercial launches, but cost-containment pressures and regional reimbursement variability require clear value articulation and innovative pricing strategies.

In Europe, Middle East & Africa, regulatory heterogeneity and varying health technology assessment frameworks necessitate region-specific evidence packages and payer engagement plans. The region's collaborative academic hubs and growing cell therapy manufacturing footprint provide opportunities for cross-border trial networks and shared manufacturing consortia, while reimbursement timelines often influence launch sequencing and market access pathways.

The Asia-Pacific region is characterized by rapid investment in manufacturing capacity, increasing clinical trial activity, and diverse regulatory approaches that range from expedited pathways in some jurisdictions to nascent frameworks in others. Localized production and regulatory alignment efforts can create competitive advantages, particularly for companies seeking to mitigate trade-related cost pressures and accelerate patient access. Each region thus demands tailored operational plans that reconcile regulatory expectations, payer environments, clinical capabilities, and supply chain considerations to support sustainable expansion.

Company-level competitive advantage increasingly derives from integrated capabilities spanning platform science, scalable manufacturing, and proactive payer and regulatory engagement

Key company-level insights center on capability convergence, partnership strategies, and vertical integration decisions that determine competitive positioning. Leading clinical-stage organizations are combining receptor engineering expertise with translational pipelines to broaden indication coverage, while others focus on platform robustness to support multiple product candidates. Contract development and manufacturing organizations are evolving beyond pure production roles into strategic partners offering process development, analytical services, and quality-by-design capabilities that reduce time-to-clinic for sponsors.

Strategic partnerships between developers, academic centers, and manufacturing providers are increasingly common, enabling sharing of specialized knowledge such as vector optimization, potency assays, and cryopreservation techniques. Companies that invest in modular, automated manufacturing assets and data-integrated quality systems have greater flexibility to manage different therapy types and scale production across autologous and allogeneic formats. Additionally, those that proactively engage with regulators and payers to define evidence-generation pathways gain advantage in market access negotiations.

Competitive differentiation also emerges from how companies address cost-to-serve challenges through process intensification, supply chain diversification, and innovative commercial contracting. Organizations that balance clinical differentiation with operational excellence are better positioned to transition from small-batch clinical supply to reliable commercial distribution while maintaining compliance with evolving regulatory expectations.

A pragmatic playbook for leadership to align manufacturing automation, supply chain diversification, evidence generation, and stakeholder engagement to accelerate translation and adoption

Industry leaders should adopt a multi-pronged approach that aligns scientific ambition with pragmatic operational execution. First, prioritize investments in manufacturing automation and closed-system process development to reduce variability, lower labor dependency, and compress turnaround times. This operational foundation enables more consistent product quality and supports flexible responses to demand fluctuations.

Second, diversify supplier networks for critical inputs and implement strategic inventory policies to mitigate exposure to trade volatility and tariff-driven cost shifts. Simultaneously, evaluate nearshoring or regionalization of key production steps to reduce logistical complexity and improve responsiveness to regional markets. Third, pursue evidence-generation strategies that blend randomized data with real-world outcomes and registry-driven longitudinal follow-up to meet both regulatory and payer requirements for durable benefit.

Fourth, cultivate partnerships across academic, clinical, and manufacturing ecosystems to leverage external capabilities while retaining strategic control over core platform technologies. Fifth, engage early and iteratively with regulatory authorities and payers to define trial endpoints, health-economic models, and reimbursement mechanisms that align clinical value with sustainable pricing. Finally, strengthen commercial capabilities by developing outcome-based contracting frameworks and by building clinical support programs that facilitate adoption in diverse care settings. Together, these recommendations provide a roadmap to manage complexity while accelerating patient access and commercial viability.

A transparent, triangulated methodology combining expert interviews, clinical and regulatory documentation, and manufacturing process analysis to ensure robust and actionable insights

The research underpinning this executive summary synthesizes primary and secondary sources using a triangulated approach to ensure analytical rigor and relevance. Primary inputs included structured interviews with clinical investigators, manufacturing executives, and regulatory consultants, complemented by advisory sessions with payers and hospital administrators to capture operational and reimbursement perspectives. These qualitative inputs were systematically mapped against public regulatory filings, peer-reviewed literature, and industry disclosures to validate trends and identify divergences between claimed capabilities and observed operational performance.

Data analysis integrated process-level insights from manufacturing workshops with trial design and endpoint evaluations drawn from clinical registries and published studies. Where possible, methodological triangulation was applied by cross-referencing interview findings with documentary evidence and expert panel feedback. Quality control procedures included independent review of thematic findings, validation of technical assertions by subject-matter experts, and iterative refinement based on stakeholder responses. This layered approach ensured that conclusions reflect both the current state of technology and pragmatic operational constraints encountered in real-world deployment.

Synthesis of scientific promise and operational imperatives demonstrating that sustainable commercialization of T-cell therapies requires integrated technical, regulatory, and commercial execution

T-cell therapies occupy a transformative space in modern medicine, offering potentially durable solutions across oncology, infectious disease, and autoimmune indications. The field is simultaneously enabling clinical breakthroughs and confronting supply chain, manufacturing, and reimbursement realities that will determine the pace of patient access. Strategic decisions about cell source, therapeutic modality, manufacturing model, and regional expansion will be decisive for organizations aiming to translate scientific promise into lasting clinical and commercial impact.

Stakeholders who align technical innovation with operational scalability, regulatory foresight, and payer-centric evidence generation will derive competitive advantage. Conversely, those who underestimate the integration challenges across clinical, manufacturing, and commercial domains risk delayed launches and constrained uptake. In sum, the pathway to sustainable growth in T-cell therapy requires both continued scientific ingenuity and disciplined execution across the entire value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. T-Cell Therapy Market, by Indication

  • 8.1. Autoimmune Diseases
    • 8.1.1. Multiple Sclerosis
    • 8.1.2. Psoriasis
    • 8.1.3. Rheumatoid Arthritis
  • 8.2. Infectious Diseases
    • 8.2.1. Hepatitis B
    • 8.2.2. Hepatitis C
    • 8.2.3. HIV
  • 8.3. Oncology
    • 8.3.1. Leukemia
    • 8.3.2. Lymphoma
    • 8.3.3. Multiple Myeloma
    • 8.3.4. Solid Tumors
      • 8.3.4.1. Breast Cancer
      • 8.3.4.2. Lung Cancer
      • 8.3.4.3. Melanoma

9. T-Cell Therapy Market, by Therapy Type

  • 9.1. CAR T Cell Therapy
  • 9.2. TCR T Cell Therapy
  • 9.3. TIL Therapy

10. T-Cell Therapy Market, by Manufacturing Model

  • 10.1. Contract Manufacturing
  • 10.2. In-House Manufacturing

11. T-Cell Therapy Market, by Cell Source

  • 11.1. Allogeneic
  • 11.2. Autologous

12. T-Cell Therapy Market, by End User

  • 12.1. Hospital
  • 12.2. Research Institute
  • 12.3. Specialty Clinic

13. T-Cell Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. T-Cell Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. T-Cell Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States T-Cell Therapy Market

17. China T-Cell Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Adaptimmune Therapeutics PLC
  • 18.6. Allogene Therapeutics, Inc.
  • 18.7. Amgen Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. Atara Biotherapeutics, Inc.
  • 18.10. Autolus Therapeutics PLC
  • 18.11. Bluebird Bio, Inc.
  • 18.12. Bristol-Myers Squibb Company
  • 18.13. Caribou Biosciences, Inc.
  • 18.14. Cartesian Therapeutics, Inc.
  • 18.15. Cellectis S.A.
  • 18.16. CRISPR Therapeutics AG
  • 18.17. Fate Therapeutics, Inc.
  • 18.18. Gilead Sciences, Inc.
  • 18.19. Gracell Biotechnologies Inc.
  • 18.20. Immatics Biotechnologies GmbH
  • 18.21. Immunocore Ltd.
  • 18.22. IN8Bio, Inc.
  • 18.23. Johnson & Johnson Services, Inc.
  • 18.24. Mustang Bio, Inc.
  • 18.25. Novartis AG
  • 18.26. Poseida Therapeutics, Inc.
  • 18.27. Precision BioSciences, Inc.
  • 18.28. Tmunity Therapeutics, Inc.
  • 18.29. Vor Biopharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. GCC T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. G7 T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. G7 T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 217. G7 T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 224. NATO T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 225. NATO T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. NATO T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 230. NATO T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)